Daniel Ebner
Group Head / PI and Member of congregation
The High Throughput Screening Facility is a major component of the Target Discovery Institute (or TDI) which is a new research centre initiated by the Nuffield Department of Medicine and the University of Oxford with a mandate to develop new target screening methodologies, investigate disease pathways as a means for identifying 'drug targets' and advance therapeutically relevant targets for drug development.
The aim of the high throughput screening facility at the TDI is to provide research scientists with access to a comprehensive, cost-effective facility capable of running high throughput cell based small compound and RNAi screens as well as biochemical small compound screens
Recent publications
-
Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study
Journal article
Eyre DW. et al, (2020), eLife, 9
-
ReN VM spheroids in matrix: A neural progenitor three-dimensional in vitro model reveals DYRK1A inhibitors as potential regulators of radio-sensitivity
Journal article
Wan X. et al, (2020), Biochemical and Biophysical Research Communications
-
A Semi-automated and Scalable 3D Spheroid Assay to Study Neuroblast Migration.
Journal article
Ducker M. et al, (2020), Stem cell reports
-
Quality Control of ER Membrane Proteins by the RNF185/Membralin Ubiquitin Ligase Complex
Journal article
van de Weijer ML. et al, (2020), Molecular Cell
-
HighVia—A Flexible Live-Cell High-Content Screening Pipeline to Assess Cellular Toxicity
Journal article
Howarth A. et al, (2020), SLAS DISCOVERY: Advancing the Science of Drug Discovery, 247255522092397 - 247255522092397